North American Trial will Determine Effectiveness of Laser Acupuncture
for Reducing Addiction to Nicotine, Alcohol and Drugs
MISSISSAUGA, ON, Jan. 22 /CNW/ - MedX Health Corp., (TSXV.MDX) a global
leader in developing drug free, non-invasive low level laser and light therapy
for tissue repair and pain relief, today announced that the company has
received FDA Institutional Review Board (IRB) approval to study the
effectiveness of laser acupuncture for addiction to nicotine, alcohol and
drugs. This study, to be launched in both Canada and the United States, will
be an open, multi-center trial treating patients with addictions to assess the
effectiveness of using the MedX laser probe as a means of controlling the need
for these substances.
The most common addictions are to legal substances, including nicotine,
alcohol and drugs such as prescription painkillers. Each can lead to a number
of debilitating conditions and even death.
"While the use of laser therapy in addiction is not a new concept, it has
not been well-documented and it is important that MedX conduct these
meaningful studies to confirm the efficacy of our laser and established
treatment protocols for these addictions. This would lead to a more
cost-effective way to treat addiction," states Steve Guillen, president and
CEO of MedX Health. "This is just the beginning of a number of trials we plan
to launch in laser acupuncture with our MedX laser probe. Our goal is to
institute a safe and effective standard of care for those suffering from
substance abuse and the serious medical conditions that can result from drug,
alcohol, and smoking addictions," adds Guillen.
"Each clinic that participates in the study will use our MedX laser probe
with established protocols and will be responsible for documenting and sending
us data regularly, which will be analyzed and published on a yearly basis,"
explains Anita Saltmarche, RN, MHSc, vice president of clinical and scientific
About the trial
The MedX multi-center trial will determine the effectiveness of laser
acupuncture for treating a number of major health conditions that
significantly contribute to morbidity and mortality. Drug, alcohol, and
smoking addictions cost individuals, society and the health care system
millions in treating these addictions, including various cessation programs.
MedX will be working with sites across the US and Canada to enroll
patients interested in participating in studies using low level laser therapy
for auricular acupuncture for smoking, drug or alcohol abuse.
The comprehensive addiction treatment program and study includes
well-established staff education and training, marketing materials and
innovative low level laser technology to ensure a high quality, standardized
treatment protocol. The research results will assist in guiding clinical
practice and increasing the likelihood of successful outcomes for patients
experiencing an array of significant health issues.
About Laser Auriculotherapy
Laser Auriculotherapy is the stimulation of points on the external ear
and in some cases meridian points in other parts of the body, to aid many
health conditions, especially pain, stress and addiction. Based on years of
experience experts believe that this stimulation will lead to a reduction in
the patient's need for the substances. The reduced cravings outcome with laser
auricular acupuncture is based on the recent observation that the ear
represents a door into the endocrine and autonomic nervous systems. In 1997, a
consensus panel of the US National Institutes of Health gave approval to the
practice of acupuncture, which included an evaluation of those studies which
supported the use of ear acupuncture for pain and addiction.
About Tobacco, Alcohol and Drug Addiction
According to the Centers for Disease Control, tobacco use remains the
leading preventable cause of disease and deaths in the US, causing
approximately 440,000 premature deaths each year resulting in 13.2 years of
potential life lost for male smokers, and 14.5 years lost for female smokers.
This is associated with an estimated $192 billion in annual medical
expenditures and lost productivity.
A study published in the Journal of the American Medical Association in
2004 found that excessive alcohol consumption is the third leading preventable
cause of death in the United States and is associated with multiple adverse
health consequences, including liver cirrhosis, various cancers, unintentional
injuries, and violence. In 2001, an estimated 75,766 alcohol-attributable
deaths (AADs) and 2.3 million years of potential life lost, or approximately
30 years of life lost on average per AAD, were attributable to excessive
alcohol use in 2001.
According to the National Institutes for Drug Abuse, addiction to
alcohol, nicotine, and illegal substances cost Americans upwards of half a
trillion dollars a year, considering their combined medical, economic,
criminal, and social impact. Every year, abuse of illicit drugs and alcohol
contributes to the death of more than 100,000 Americans.
MedX Health is a global leader in the design, manufacturing and
distribution of quality low level laser and light therapy technology for use
in numerous medical settings that provide patients with non-invasive,
drug-free solutions for improving clinical outcomes. MedX's innovative
Laser/Light Therapy devices not only enhance the rehabilitation process and
clinical outcomes for people seeking relief from pain and other physical
ailments, but can now help individuals to overcome addictions.
The TSX Venture Exchange does not accept responsibility for the adequacy
or accuracy of this press release.
This press release contains "forward-looking information" within the
meaning of applicable Canadian securities legislation. Such forward-looking
information may include statements regarding the Company's future plans,
objectives, performance, growth, profits, operating expenses or its underlying
assumptions. Generally, forward-looking information can be identified by the
use of forward-looking terminology such as "plans", "expects", or "does not
expect", "is expected", "budget", "scheduled", "estimates", "forecasts",
"intends", "anticipates", or "does not anticipate", or "believes" or
variations of such words and phrases or state that certain actions, events or
results "may", "could", "would", "might", or "will be taken", "occur", or "be
achieved". Forward-looking information is subject to known and unknown risks,
uncertainties and other factors that may cause the actual results, level of
activity, performance or achievements of MedX to be materially different from
those expressed or implied by such forward-looking information, including
uncertainty of successful development of new products, uncertainty of
successful manufacturing or marketing of products, uncertainty of commercial
acceptance of products, uncertainty concerning governmental regulation,
dependency on key employees and relationships, rapid technological changes,
foreign currency fluctuations. MedX does not undertake to update any
forward-looking information, except in accordance with applicable securities
For further information:
For further information: Investors: Steve Guillen, President and Chief
Executive Officer, MedX Health Corp., Phone: (905) 826-0766,
firstname.lastname@example.org; Media: Terri Clevenger, Continuum Health Communications,
Phone (203) 227-0209, Email: email@example.com